12,300 results match your criteria Imaging in Small Cell Lung Cancer

PET Imaging of Lung Cancers in Precision Medicine: Current Landscape and Future Perspective.

Mol Pharm 2022 Jun 30. Epub 2022 Jun 30.

Department of Thoracic Surgery, Renji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 200217, China.

Despite the recent advances in cancer treatment, lung cancer remains the leading cause of cancer mortality worldwide. Immunotherapies using immune checkpoint inhibitors (ICIs) achieved substantial efficacy in nonsmall cell lung cancer (NSCLC). Currently, most ICIs are still a monoclonal antibody (mAb). Read More

View Article and Full-Text PDF

Risk Factors for Brain Metastases in Patients With Small Cell Lung Cancer: A Systematic Review and Meta-Analysis.

Front Oncol 2022 10;12:889161. Epub 2022 Jun 10.

Department of Pulmonary Diseases, GROW School for Oncology and Developmental Biology, Maastricht University Medical Center+, Maastricht, Netherlands.

The use of prophylactic cranial irradiation (PCI) for small cell lung cancer (SCLC) patients is controversial. Risk factors for brain metastasis (BM) development are largely lacking, hampering personalized treatment strategies. This study aimed to identify the possible risk factors for BM in SCLC. Read More

View Article and Full-Text PDF

[Survival analysis of unexpected small cell lung cancer following surgery].

Zhonghua Zhong Liu Za Zhi 2022 Jun;44(6):550-554

Department of Thoracic Surgery, the First Medical Center, Chinese PLA General Hospital, Beijing 100853, China.

To investigate the survival and influencing factors of unexpected small cell lung cancer following surgery. We respectively reviewed the clinical characters of 104 patients who underwent surgical treatment and be proved as small cell lung cancer by pathology between January 2000 to October 2020 in Chinese PLA General Hospital. Overall survival (OS) of patients was evaluated using Kaplan-Meier and Cox proportional hazards analysis. Read More

View Article and Full-Text PDF

Computed DWI MRI Results in Superior Capability for N-Stage Assessment of Non-Small Cell Lung Cancer Than That of Actual DWI, STIR Imaging, and FDG-PET/CT.

J Magn Reson Imaging 2022 Jun 26. Epub 2022 Jun 26.

Department of Radiology, Fujita Health University School of Medicine, Toyoake, Japan.

Background: Computed diffusion-weighted imaging (cDWI) is a mathematical computation technique that generates DWIs for any b-value by using actual DWI (aDWI) data with at least two different b-values and may improve differentiation of metastatic from nonmetastatic lymph nodes.

Purpose: To determine the appropriate b-value for cDWI to achieve a better diagnostic capability for lymph node staging (N-staging) in non-small cell lung cancer (NSCLC) patients compared to aDWI, short inversion time (TI) inversion recovery (STIR) imaging, or positron emission tomography with 2-[fluorine-18] fluoro-2-deoxy-d-glucose combined with computed tomography (FDG-PET/CT).

Study Type: Prospective. Read More

View Article and Full-Text PDF

Feasibility and clinical utility of a workflow interfacing radiation oncology lung stereotactic body radiotherapy treatment planning and diagnostic radiology.

Pract Radiat Oncol 2022 Jun 22. Epub 2022 Jun 22.

Department of Radiation Oncology, Huntsman Cancer Hospital, University of Utah. Electronic address:

Stereotactic body radiotherapy (SBRT) is commonly used to treat early stage non-small cell lung cancer (NSCLC). SBRT beam arrangements include multiple entry/exit pathways resulting in irregular low dose distributions within normal lung parenchyma. An improved understanding of post-treatment radiographic changes may improve the ability to predict clinical complications including radiation pneumonitis as well as assist in early detection of local failures. Read More

View Article and Full-Text PDF

Bone-specific response according to MDA criteria predicts immunotherapy efficacy among advanced non-small cell lung cancer (NSCLC) patients.

J Cancer Res Clin Oncol 2022 Jun 24. Epub 2022 Jun 24.

Department of Experimental, Diagnostic and Specialty Medicine, University of Bologna, Via Giuseppe Massarenti, 9, 40138, Bologna, Italy.

Purpose: The presence of bone metastasis at baseline has been associated with dismal prognosis under immunotherapy in advanced non-small cell lung cancer (NSCLC). Response Evaluation Criteria in Solid Tumors (RECIST) criteria may be limited for bone-specific response evaluation. Whether their assessment through MD Anderson (MDA) criteria predict immunotherapy efficacy is unknown. Read More

View Article and Full-Text PDF

Pembrolizumab-induced aseptic meningitis in a patient with non-small cell lung cancer: A case report and literature review of aseptic meningitis as an immune-related adverse event.

Mol Clin Oncol 2022 Jul 1;17(1):120. Epub 2022 Jun 1.

Department of Multidisciplinary Internal Medicine, Division of Respiratory Medicine and Rheumatology, Faculty of Medicine, Tottori University, Yonago, Tottori 683-8503, Japan.

Aseptic meningitis is a rare immune-related adverse event (irAE), which occurs during treatment with immune checkpoint inhibitors (ICIs). This condition has non-specific symptoms and exhibits no clear signs on magnetic resonance imaging (MRI). There are only a few reports of aseptic meningitis caused by pembrolizumab treatment for non-small cell lung cancer (NSCLC). Read More

View Article and Full-Text PDF

Combination of [Lu]Lu-DOTA-TATE Targeted Radionuclide Therapy and Photothermal Therapy as a Promising Approach for Cancer Treatment: In Vivo Studies in a Human Xenograft Mouse Model.

Pharmaceutics 2022 Jun 16;14(6). Epub 2022 Jun 16.

Department of Clinical Physiology and Nuclear Medicine & Cluster for Molecular Imaging, Copenhagen University Hospital-Rigshospitalet & Department of Biomedical Sciences, University of Copenhagen, 2100 Copenhagen, Denmark.

Peptide receptor radionuclide therapy (PRRT) relies on α- and β-emitting radionuclides bound to a peptide that commonly targets somatostatin receptors (SSTRs) for the localized killing of tumors through ionizing radiation. A Lutetium-177 (Lu)-based probe linked to the somatostatin analog octreotate ([Lu]Lu-DOTA-TATE) is approved for the treatment of certain SSTR-expressing tumors and has been shown to improve survival. However, a limiting factor of PRRT is the potential toxicity derived from the high doses needed to kill the tumor. Read More

View Article and Full-Text PDF

Management of Combined Therapy (Ceritinib, , , and Photobiomodulation) in Advanced Non-Small-Cell Lung Cancer: A Case Report.

Life (Basel) 2022 Jun 9;12(6). Epub 2022 Jun 9.

Department of Biomedical Engineering, Ming Chuan University, Taoyuan 33348, Taiwan.

The 5-year survival rate of non-small-cell lung cancer (NSCLC) is still low (<21%) despite recent improvements. Since conventional therapies have a lot of side effects, combined therapy is strongly recommended. Here, we report a patient with advanced NSCLC who received combined therapy, including ceritinib, photobiomodulation (PBM), ACGL ( (), and ()). Read More

View Article and Full-Text PDF

A Small Molecule That Promotes Cellular Senescence Prevents Fibrogenesis and Tumorigenesis.

Int J Mol Sci 2022 Jun 20;23(12). Epub 2022 Jun 20.

Osteoneurogen. Inc., Seoul 08501, Korea.

Uncontrolled proliferative diseases, such as fibrosis or cancer, can be fatal. We previously found that a compound containing the chromone scaffold (CS), ONG41008, had potent antifibrogenic effects associated with EMT or cell-cycle control resembling tumorigenesis. We investigated the effects of ONG41008 on tumor cells and compared these effects with those in pathogenic myofibroblasts. Read More

View Article and Full-Text PDF

Posterior Reversible Encephalopathy Syndrome Following Chemotherapy and Immune Checkpoint Inhibitor Combination in a Patient with Small-Cell Lung Cancer.

Diagnostics (Basel) 2022 Jun 2;12(6). Epub 2022 Jun 2.

Department of Imaging, Gustave Roussy, Université Paris-Saclay, 94805 Villejuif, France.

Posterior reversible encephalopathy syndrome (PRES) is a rare neurological complication that occurs following a sudden blood pressure increase. We report the case of a 64-year-old patient presenting PRES several hours after the administration of a combination of chemotherapy and a checkpoint inhibitor (carboplatin-etoposide-atezolizumab) for small-cell lung cancer. He presented consciousness disorders associated with partial epileptic seizure secondarily generalized. Read More

View Article and Full-Text PDF

A Prospective Study to Detect Immune Checkpoint Inhibitors Associated With Myocarditis Among Patients Treated for Lung Cancer.

Front Cardiovasc Med 2022 6;9:878211. Epub 2022 Jun 6.

Pulmonary Department, Centre Hospitalier Universitaire (CHU) Haut-Lévèque, Bordeaux, France.

Background: Immune checkpoint inhibitors (ICIs) are widely used in lung cancer management. However, myocarditis, which is a rare, yet potentially severe adverse-related event associated with ICIs, could be under-reported.

Objectives: This study is aimed to prospectively evaluate the cumulative incidence rate of myocarditis, through systematic screening, among patients receiving ICIs for lung cancer. Read More

View Article and Full-Text PDF

Leptomeningeal Metastatic L858R -mutant Lung Cancer: Prompt Response to Osimertinib in the Absence of T790M-mutation and Effective Subsequent Pulsed Erlotinib.

Onco Targets Ther 2022 14;15:659-667. Epub 2022 Jun 14.

Pharmacy Department, National Center for Cancer Care and Research, Hamad Medical Corporation, Doha, Qatar.

Leptomeningeal carcinomatosis (LMC) is a known sequel of metastatic lung cancer and its treatment is challenging. Nevertheless, treatment options for LMC due to metastatic epidermal growth factor receptor-mutant (-mutant) lung adenocarcinoma are expanding. We present a 52-year-old male patient with metastatic non-small-cell lung cancer (NSCLC). Read More

View Article and Full-Text PDF

Diagnosis and treatment of Merkel cell carcinoma: European consensus-based interdisciplinary guideline - Update 2022.

Eur J Cancer 2022 Jun 19;171:203-231. Epub 2022 Jun 19.

Universite' de Paris, INSERM U976, AP-HP, Dermatology Department, Saint Louis Hospital, Paris, France. Electronic address:

Merkel cell carcinoma (MCC) is a rare skin cancer, accounting for less than 1% of all cutaneous malignancies. It is found predominantly in white populations and risk factors include advanced age, ultraviolet exposure, male sex, immunosuppression, such as AIDS/HIV infection, haematological malignancies or solid organ transplantation, and Merkel cell polyomavirus infection. MCC is an aggressive tumour with 26% of cases presenting lymph node involvement at diagnosis and 8% with distant metastases. Read More

View Article and Full-Text PDF

Voxel-Level BED Corrected Dosimetric and Radiobiological Assessment of 2 Kinds of Hybrid Radiotherapy Planning Methods for Stage III NSCLC.

Technol Cancer Res Treat 2022 Jan-Dec;21:15330338221107966

Department of Radiation Oncology, 92323Zhongshan Hospital, Fudan University, Shanghai, China.

To access the comparative dosimetric and radiobiological advantages of two methods of intensity-modulated radiation therapy (IMRT)-based hybrid radiotherapy planning for stage III nonsmall cell lung cancer (NSCLC). Two hybrid planning methods were respectively characterized by conventional fraction radiotherapy (CFRT) and stereotactic body radiotherapy (SBRT) and CFRT and simultaneous integrated boost (SIB) planning. All plans were retrospectively completed using the 2 methods for 20 patients with stage III NSCLC. Read More

View Article and Full-Text PDF

Editorial for "Computed DWI Results in Superior Capability for N-Stage Assessment of Non-Small Cell Lung Cancer than that of Actual DWI, STIR Imaging and FDG-PET/CT".

J Magn Reson Imaging 2022 Jun 22. Epub 2022 Jun 22.

Institute for Diagnostic and Interventional Radiology, University Hospital Cologne, Kerpener Straße 62, Cologne, 50937, Germany.

View Article and Full-Text PDF

Rapid On-site Evaluation and Final Cytologic Diagnoses Correlation During Endobronchial Ultrasonography.

J Bronchology Interv Pulmonol 2022 Jul 9;29(3):191-197. Epub 2021 Sep 9.

Departments of Pulmonology.

Background: The cost-effectiveness and low rate of inadequate sampling with the use of rapid on-site evaluation (ROSE) along with endobronchial ultrasonography (EBUS) is well established. Our aim in this study was to evaluate the correlation of ROSE during EBUS and final cytologic diagnosis and also to see if ROSE might predict the subtype of lung cancer.

Patients And Methods: All consecutive subjects who attended our clinic between January 2016 and January 2019 for the evaluation of pathologic mediastinal and/or hilar lymph nodes (LNs)/mass using EBUS were enrolled into our prospective study. Read More

View Article and Full-Text PDF

Clinical quality indicators of pathways to oncological lung surgery.

N Z Med J 2022 Jun 10;135(1556):11-22. Epub 2022 Jun 10.

Cardiothoracic Surgery Registrar, Department of Cardiothoracic Surgery, Dunedin Public Hospital, Dunedin, Otago.

Aims: Multidisciplinary team (MDT) meetings are a standard of care for lung cancer management in many regions around the world. Clinical quality indicators (CQIs) can be used to assess the proficiency of these multidisciplinary teams and compare their performance against those recommended by local and international guidelines. The effectiveness of the lung cancer MDT meeting at Dunedin Public Hospital has been evaluated using CQIs with a focus on the timeliness of surgical management. Read More

View Article and Full-Text PDF

Novel Radiomic Measurements of Tumor-Associated Vasculature Morphology on Clinical Imaging as a Biomarker of Treatment Response in Multiple Cancers.

Clin Cancer Res 2022 Jun 21. Epub 2022 Jun 21.

Case Western Reserve University, Cleveland, OH, United States.

Purpose: Tumor-associated vasculature is distinguished its convolutedness, leakiness, and chaotic architecture, which facilitates the creation of a treatment resistant tumor microenvironment. Measurable differences in these attributes might help stratify patients by potential benefit of systemic therapy. In this work, we present a new category of radiomic quantitative tumor-associated vasculature (QuanTAV) biomarkers and investigate their ability to predict outcomes across multiple cancers, imaging modalities, and treatment regimens. Read More

View Article and Full-Text PDF

Use of Preoperative FDG PET/CT and Survival of Patients with Resectable Non-Small Cell Lung Cancer.

Radiology 2022 Jun 21:212798. Epub 2022 Jun 21.

From the Graduate Institute of Business Administration, College of Management (W.M.C., M.C., J.G.H., T.S.L., B.C.S., S.Y.W.), and Artificial Intelligence Development Center (B.C.S., S.Y.W.), Fu Jen Catholic University, Taipei, Taiwan; Big Data Center (W.M.C., S.Y.W.), Division of Radiation Oncology (S.Y.W.), and Cancer Center (S.Y.W.), Lo-Hsu Medical Foundation, Lotung Poh-Ai Hospital, No. 111, Section 3, Hsing-Long Rd, Taipei 116, Taiwan; Department of Food Nutrition and Health Biotechnology (S.Y.W.) and Department of Healthcare Administration (S.Y.W.), College of Medical and Health Science, Asia University, Taichung, Taiwan; Centers for Regional Anesthesia and Pain Medicine, Taipei Municipal Wan Fang Hospital, Taipei Medical University, Taipei, Taiwan (S.Y.W.); and Department of Management, College of Management, Fo Guang University, Yilan, Taiwan (S.Y.W.).

Background The added value of preoperative PET/CT for the overall survival of patients with resectable non-small cell lung cancer (NSCLC) is unknown. Purpose To investigate the association of the use of preoperative PET/CT on survival of patients with resectable stage I-IIIB NSCLC. Materials and Methods In this retrospective study, patients with resectable stage I-IIIB NSCLC who underwent thoracic surgery from January 1, 2009, to December 31, 2018, from the Taiwan Cancer Registry were included. Read More

View Article and Full-Text PDF

Construction and validation of a nomogram based on N6-Methylandenosine-related lncRNAs for predicting the prognosis of non-small cell lung cancer patients.

Cancer Med 2022 Jun 21. Epub 2022 Jun 21.

Department of Respiratory and Critical Care Medicine, NHC Key Laboratory of Pulmonary Diseases, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China.

Background: The N6-methyladenosine (m A) can modify long non-coding RNAs (lncRNAs), thereby influencing a wide array of biological functions. However, the prognosis of m A-related lncRNAs (m ARLncRNAs) in non-small cell lung cancer (NSCLC) remains largely unknown.

Methods: Pearson correlation analysis was used to identify m ARLncRNAs in 1835 NSCLC patients and with the condition (|Pearson R| > 0. Read More

View Article and Full-Text PDF

Circular RNA EPB41 expression predicts unfavorable prognoses in NSCLC by regulating miR-486-3p/eIF5A axis-mediated stemness.

Cancer Cell Int 2022 Jun 20;22(1):219. Epub 2022 Jun 20.

Shanghai Key Laboratory of Molecular Imaging, Shanghai University of Medicine and Health Sciences, 279 Zhouzhu Road, Pudong New Area, Shanghai, 201318, People's Republic of China.

Dysregulation of circular RNAs (circRNAs) has recently been found to play an important role in the progression and development of cancers such as non-small cell lung cancer (NSCLC). Yet the functions of many circRNAs in NSCLC remain unclear. In this study, the circRNA expression profiles in NSCLC tumor tissues and adjacent non-tumorous tissues were detected by high-throughput sequencing. Read More

View Article and Full-Text PDF

Access to Care Metrics in Stage I Lung Cancer: Improved Access Is Associated with Improved Survival.

Ann Thorac Surg 2022 Jun 17. Epub 2022 Jun 17.

Division of Cardiothoracic Surgery, Department of Surgery, Washington University School of Medicine, St. Louis, MO; VA St. Louis Health Care System, St. Louis, MO.

Background: Equitable access to care is a critical component of comprehensive surgical lung cancer management. Despite this, quality measures (QMs) assessing pre-operative access to care are lacking. We determined several pre-operative QMs based on contemporary treatment guidelines and hypothesized that poor access to care was associated with worse outcomes. Read More

View Article and Full-Text PDF

Synthesis of a versatile mitochondria-targeting small molecule for cancer near-infrared fluorescent imaging and radio/photodynamic/photothermal synergistic therapies.

Mater Today Bio 2022 Jun 7;15:100316. Epub 2022 Jun 7.

School of Medicine, University of Electronic Science and Technology of China, Chengdu, Sichuan, 610054, China.

Although as a mainstay modal for cancer treatment, the clinical effect of radiotherapy (RT) does not yet meet the need of cancer patients. Developing tumour-preferential radiosensitizers or combining RT with other treatments has been acknowledged highly necessary to enhance the efficacy of RT. The present study reported a multifunctional bioactive small-molecule (designated as IR-83) simultaneously exhibiting tumour-preferential accumulation, near-infrared imaging and radio/photodynamic/photothermal therapeutic effects. Read More

View Article and Full-Text PDF

[F]FDG-PET/CT radiomics and artificial intelligence in lung cancer: Technical aspects and potential clinical applications.

Semin Nucl Med 2022 Jun 15. Epub 2022 Jun 15.

Division of Molecular Imaging and Theranostics, Department of Nuclear Medicine, University Hospital Salzburg, Paracelsus Medical University, Salzburg, Austria. Electronic address:

Lung cancer is the second most common cancer and the leading cause of cancer-related death worldwide. Molecular imaging using [F]fluorodeoxyglucose Positron Emission Tomography and/or Computed Tomography ([F]FDG-PET/CT) plays an essential role in the diagnosis, evaluation of response to treatment, and prediction of outcomes. The images are evaluated using qualitative and conventional quantitative indices. Read More

View Article and Full-Text PDF

Dosimetric predictors of pneumonitis in locally advanced non-small cell lung cancer patients treated with chemoradiation followed by durvalumab.

Lung Cancer 2022 Jun 13;170:58-64. Epub 2022 Jun 13.

Departments of Radiation Oncology and Biostatistics & Information, Mayo Clinic, 200 1st St SW, Rochester, MN, USA. Electronic address:

Objectives: The incidence and predictors of pneumonitis for patients with unresectable, locally advanced non-small cell lung cancer (NSCLC) in the era of consolidation durvalumab have yet to be fully elucidated. In this large single institution analysis, we report the incidence of and factors associated with grade 2 + pneumonitis in NSCLC patients treated with the PACIFIC regimen.

Materials And Methods: We identified all patients treated at our institution with definitive CRT followed by durvalumab from 2018 to 2021. Read More

View Article and Full-Text PDF

A multi-classification model for non-small cell lung cancer subtypes based on independent subtask learning.

Med Phys 2022 Jun 17. Epub 2022 Jun 17.

Beijing Advanced Innovation Center for Biomedical Engineering, School of Biological Science and Medical Engineering, Beihang University, Beijing, China.

Purpose: The non-small cell lung cancer (NSCLC) can be divided into adenocarcinoma (ADC), squamous cell carcinoma (SCC), large cell carcinoma (LCC), and not otherwise specified (NOS), which is crucial for clinical decision-making. However, current related researches are rare for the complex multi-classification of NSCLC, mainly due to the serious data imbalance, the difficulty to unify the feature space, and the complicated decision boundary among multiple subtypes. The machine learning method of traditional "one-vs-one" (OVO) is difficult to solve these problems and achieve good results. Read More

View Article and Full-Text PDF

Reappraising the clinical usability of consolidation-to-tumor ratio on CT in clinical stage IA lung cancer.

Insights Imaging 2022 Jun 17;13(1):103. Epub 2022 Jun 17.

Department of Radiology and Center for Imaging Science, Samsung Medical Center, Sungkyunkwan University School of Medicine, 81 Irwon-Ro, Gangnam-Gu, Seoul, 06351, Korea.

Objectives: Ground-glass opacity (GGO) on computed tomography is associated with prognosis in early-stage non-small cell lung cancer (NSCLC) patients. However, the stratification of the prognostic value of GGO is controversial. We aimed to evaluate clinicopathologic characteristics of early-stage NSCLC based on the consolidation-to-tumor ratio (CTR), conduct multi-pronged analysis, and stratify prognosis accordingly. Read More

View Article and Full-Text PDF

Neoadjuvant Immunotherapy: Leveraging the Immune System to Treat Early-Stage Disease.

Am Soc Clin Oncol Educ Book 2022 Apr;42:1-15

Division of Cancer Medicine, Department of Thoracic/Head & Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX.

Given the success of immunotherapy in treating patients with metastatic disease in a variety of tumor types, there is tremendous enthusiasm for expanding the use of immunotherapy to those with early-stage cancer. Administering immunotherapy in the neoadjuvant, preoperative setting is a biologically sound approach because preclinical studies have shown that stronger and broader immune responses can be generated if immunotherapy is administered while the tumor and/or draining lymph nodes are intact. It is therefore likely that administering immunotherapy preoperatively will generate optimal immune responses, leading to high rates of pathologic response as well as improved long-term survival. Read More

View Article and Full-Text PDF

Surgical resection, radiotherapy and percutaneous thermal ablation for treatment of stage 1 non-small cell lung cancer: protocol for a systematic review and network meta-analysis.

BMJ Open 2022 Jun 16;12(6):e057638. Epub 2022 Jun 16.

Division of Vascular and Interventional Radiology, Department of Diagnostic Radiology and Nuclear Medicine, University of Maryland School of Medicine, Baltimore, Maryland, USA

Introduction: Non-small cell lung cancer (NSCLC) makes up the majority of lung cancer cases. Currently, surgical resection is the gold standard of treatment. However, as patients are becoming medically more complex presenting with advanced disease, minimally invasive image-guided percutaneous ablations are gaining popularity. Read More

View Article and Full-Text PDF